Merck/Ridgeback’s COVID-19 Drug Molnupiravir Met EUA Bar, But More Data Needed For Full Approval – US FDA

 
• By Sue Sutter
Uneven bars
Molnupiravir met the low bar for emergency authorization but will need more data to surmount the higher bar for full approval. • Source: Alamy

More from Product Reviews

More from Pink Sheet